Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.64 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.64 |
| ▸ | AGT | P01019 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL2576559 | 0.99 | AGTR1 (0.63) | AGTR1AGTR2AGT | |
| SCHEMBL2575939 | 0.93 | AGTR1 (0.55) | AGTR1AGTR2 | |
| SCHEMBL1758316 | 0.92 | AGTR1 (0.60) | AGTR1AGTR2AGT | |
| SCHEMBL7308543 | 0.90 | AGTR1 (0.65) | AGTR1AGTR2 | |
| SCHEMBL7304474 | 0.89 | AGTR1 (0.64) | AGTR1AGTR2AGT | |
| SCHEMBL1308518 | 0.88 | AGTR1 (0.65) | AGTR1AGTR2 | |
| SCHEMBL8861132 | 0.87 | AGTR2 (0.55) | AGTR1AGTR2AGT | |
| Water SCHEMBL2576557 | 0.87 | AGTR1 (0.64) | AGTR1AGTR2 | |
| SCHEMBL14855210 | 0.87 | AGTR1 (0.62) | AGTR1AGTR2AGT | |
| SCHEMBL14855527 | 0.85 | AGTR1 (0.66) | AGTR1AGTR2AGT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076492-B2 | Process for preparing trityl olmesartan medoxomil and olmesartan medoxomil | CIPLA LIMITED (IN) | 2011-12-13 | — | — | US | disclosed |
| US-8048904-B2 | Process for the preparation of olmesartan medoxomil | MATRIX LABORATORIES LTD. (IN) | 2011-11-01 | — | — | US | disclosed |
| EP-2334668-A1 | PROCESS FOR PREPARING OLMESARTAN MEDOXOMIL INTERMEDIATE | Krka Tovarna Zdravil, D.D., Novo Mesto (SI) | 2011-06-22 | — | — | EP | disclosed |
| EP-2244575-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20100160643-A1 | Process for Preparing Trityl Olmesartan Medoxomil and Olmesartan Medoxomil | CIPLA LIMITED (IN) | 2010-06-24 | — | — | US | disclosed |
| WO-2010026255-A1 | PROCESS FOR PREPARING OLMESARTAN MEDOXOMIL INTERMEDIATE | KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2010-03-11 | — | — | WO | disclosed |
| US-20090281327-A1 | PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL | MATRIX PHARMACORP PRIVATE LIMITED (IN) | 2009-11-12 | — | — | US | disclosed |
| WO-2009094242-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| EP-2074116-A2 | PROCESS FOR PREPARING TRITYL OLMESARTAN MEDOXOMIL AND OLMESARTAN MEDOXOMIL | Cipla Limited (IN) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008043996-A2 | PROCESS FOR PREPARING TRITYL OLMESARTAN MEDOXOMIL AND OLMESARTAN MEDOXOMIL | CIPLA LIMITED (IN) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160643-A1 | Process for Preparing Trityl Olmesartan Medoxomil and Olmesartan Medoxomil | MED1, AGTR1, MED12 | AGTR1 2/4885AGTR2 4/4885AGT 39/4885 |
| US-20090281327-A1 | PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL | MED1, TET1, AGTR1 | AGTR1 3/4885AGTR2 5/4885AGT 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.